Goodbody Health Inc. - Update on Completion of Continuation
RNS Number : 9672W
Goodbody Health Inc.
23 August 2022

23rd August 2022

Goodbody Health Inc.

(Renamed: Goodbody Health Limited)

("Goodbody Health", or the "Company")

Goodbody Health Provides Shareholders Update on Completion of Continuation

Goodbody Health (AQSE: GDBY) is pleased to confirm the completion of the Company's continuation to Guernsey, effective August 19th, 2022, as previously announced which changes the name from Goodbody Health Inc. to Goodbody Health Limited.  Also as previously announced, the Company's voluntary delisting from the CSE occurred at the close of trading on August 17, 2022 after the suspension of trading on the AQSE on August 16, 2022. Shortly thereafter the ten for one share consolidation of the Company's issued and outstanding shares became effective on August 18, 2022. Following the consolidation, and upon the re-commencement of trading on the AQSE, the Company will have 36,496,276 Ordinary Shares issued and outstanding.


Trading is anticipated to resume on the AQSE on Wednesday, the 24th August 2022 following the continuation.


The Company has published Frequently Asked Questions (FAQs) in regards to the information and the continuation procedures relevant to shareholders on its website to be found at


Geremy Thomas, Executive Chairman, said: "This move is part of a simplification of the business, allowing the company management to focus on the London market and the growth of the diagnostic testing business. We look forward to exciting times ahead."


The Directors of the Company accept responsibility for the contents of this announcement.


For further information:

Marc Howells

Chief Executive Officer

Goodbody Health Inc.

+44 (0) 20 7971 1255

Anne Tew

Chief Financial Officer

Goodbody Health Inc.

+44 (0) 20 7971 1255



AQSE Corporate Adviser

Peterhouse Capital Limited

Guy Miller/Mark Anwyl

+44 (0) 20 7469 0930



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.